Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2022
Kountouras, J., Papaefthymiou A., Polyzos S. A., Kazakos E., Vardaka E., Touloumtzi M., et al. (2022).  Impact of Active Helicobacter pylori Infection-related Metabolic Syndrome on Systemic Arterial Hypertension.. Arq Bras Cardiol. 119(3), 502-504.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Vardaka E., Touloumtzi M., et al. (2022).  Letter to the Editor Regarding "The Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomy" by Abeid et al.. Obes Surg. 32(6), 2079-2080.
Polyzos, S. A., Lambrinoudaki I., & Goulis D. G. (2022).  Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease.. Hormones (Athens).
Polyzos, S. A., Hill M. A., Fuleihan G. El- Hajj, Gnudi L., Kim Y-B., Larsson S. C., et al. (2022).  Metabolism, Clinical and Experimental: seventy years young and growing.. Metabolism. 155333.
Polyzos, S. A., & Mantzoros C. S. (2022).  Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need.. Curr Med Res Opin. 38(6), 885-888.
Vachliotis, I. D., Anastasilakis A. D., Goulas A., Goulis D. G., & Polyzos S. A. (2022).  Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.. Diabetes Obes Metab. 24(9), 1702-1720.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Tzitiridou-Chatzopoulou M., Chatzopoulos D., et al. (2022).  Potential impact of Helicobacter pylori and metabolic syndrome-related non-alcoholic fatty liver disease on cardio-cerebrovascular disease.. Metabolism. 135, 155276.
Kountouras, J., Papaefthymiou A., Polyzos S. A., & Doulberis M. (2022).  Potential Impact of Helicobacter pylori Infection on Pancreatic Cancer Pathophysiology.. J Gastrointest Cancer.
Kountouras, J., Doulberis M., Polyzos S. A., Tzitiridou M., Chatzopoulos D., Gialamprinou D., et al. (2022).  A potential impact of Helicobacter pylori-related metabolic syndrome on early and long-term outcomes of bariatric surgery.. Gastrointest Endosc. 96(6), 1088-1089.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Kyrailidi F., & Doulberis M. (2022).  Potential impact of Helicobacter pylori-related metabolic syndrome on arterial hypertension outcomes.. Am J Hypertens.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Kouvari, M., Polyzos S. A., Chrysohoou C., Skoumas J., Pitsavos C. S., Panagiotakos D. B., et al. (2022).  Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study.. Clin Nutr. 41(6), 1281-1289.
2021
Boutari, C., Polyzos S. A., & Mantzoros C. S. (2021).  Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward.. Metabolism. 122, 154781.
Polyzos, S. A., Tournis S., Goulas A., Kollia P., & Whyte M. P. (2021).  Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.. J Musculoskelet Neuronal Interact. 21(4), 584-589.
Polyzos, S. A., Xanthopoulos K., & Kountouras J. (2021).  Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. Curr Vasc Pharmacol.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Potoupni, V., Georgiadou M., Chatzigriva E., Polychronidou G., Markou E., Gakis C. Zapantis, et al. (2021).  Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Appelman-Dijkstra N. M., Ntenti C., Mandanas S., et al. (2021).  Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.. Calcif Tissue Int.
Polyzos, S. A., & Mantzoros C. S. (2021).  Diabetes mellitus: 100 years since the discovery of insulin.. Metabolism. 118, 154737.
Makras, P., Appelman-Dijkstra N. M., Papapoulos S. E., van Wissen S., Winter E. M., Polyzos S. A., et al. (2021).  The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.. J Clin Endocrinol Metab.
Papaefthymiou, A., Doulberis M., Karafyllidou K., Chatzimichael E., Deretzi G., Exadaktylos A. K., et al. (2021).  Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.. Minerva Endocrinol (Torino).
Anastasilakis, A. D., Polyzos S. A., Makras P., Trovas G., Yavropoulou M. P., & Tournis S. (2021).  Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.. J Clin Densitom.
Makri, E., Goulas A., & Polyzos S. A. (2021).  Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.. Arch Med Res. 52(1), 25-37.
Polyzos, S. A., Papaefthymiou A., Doulberis M., Mavridoglou G., & Kountouras J. (2021).  Helicobacter pylori infection and diabetes mellitus.. Diabetes Metab Syndr. 15(3), 845-846.
Doulberis, M., Pierre N. Thierry, Manzini G., Papaefthymiou A., Kountouras J., Klukowska-Rötzler J., et al. (2021).   Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients.. Microorganisms. 9(7), 

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές